Cannabis medicines validation specialist Zelira Therapeutics Ltd (ASX:ZLD) has received the final clinical report for its Phase 1 dose escalation trial in chronic pain patients on long-term high-dose opioid treatment.

The phase 1 dose-escalation trial was designed to assess the safety of Zelira’s cannabis formulation (ZTL- 103) in chronic pain patients already on long-term high-dose opioid treatment.

TechInvest – Zelira obtains key data in cannabis dose escalation study